No abstract

The 2019 Coronavirus Disease (COVID-19) has become an unprecedented public crisis. We retrospectively investigated the clinical data of 197 COVID-19 patients and identified 88 patients as disease aggravation cases. Compared with patients without disease aggravation, the aggravation cases had more comorbidities, including hypertension (25.9%) and diabetes (20.8%), and presented with dyspnoea (23.4%), neutrophilia (31.5%), and lymphocytopenia (46.7%). These patients were more prone to develop organ damage in liver, kidney, and heart (P < 0.05). A multivariable regression analysis showed that advanced age, comorbidities, dyspnea, lymphopenia, and elevated levels of Fbg, CTnI, IL-6, and serum ferritin were significant predictors of disease aggravation. Further, we performed a Kaplan–Meier analysis to evaluate the prognosis of COVID-19 patients, which suggested that 64.9% of the patients had not experienced ICU transfers and survival from the hospital.

In December 2019, with the outbreak of the unidentified pneumonia, a novel coronavirus was confirmed to be accountable for this disease and aroused great attention around the entire world. The World Health Organization (WHO) officially named the novel coronavirus as SARS-CoV-2 and the pneumonia of unknown origin as Corona Virus Disease (COVID-19). At present, COVID-19 has become an unprecedented global health crisis, with over 6 million confirmed cases and 350,000 deaths worldwide.The main manifestations are usually fever, cough, fatigues, breathlessness, and among others. To date, specific antiviral agents against the SARS-CoV-2 are not available. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. In this review, we detail current evidence and understanding of the etiology, epidemiology, clinical characteristics, treatment of COVID-19, which may provide a reference for future studies and help in the prevention and control of the COVID-19 epidemic.